索卡佐利单抗
索卡佐利单抗用途
索唑单抗(ZKAB001)是一种抗PD-L1单克隆抗体。Socazolimab在治疗复发或转移性癌症方面具有持久的安全性和疗效。Socazolimab在小细胞肺癌、食管鳞癌(ESCC)、晚期尿路上皮癌和骨肉瘤中也有潜在应用[1][2][3][4][5]。
索卡佐利单抗名称
索卡佐利单抗生物活性
[ 描述 ]:
索唑单抗(ZKAB001)是一种抗PD-L1单克隆抗体。Socazolimab在治疗复发或转移性癌症方面具有持久的安全性和疗效。Socazolimab在小细胞肺癌、食管鳞癌(ESCC)、晚期尿路上皮癌和骨肉瘤中也有潜在应用[1][2][3][4][5]。
[ 相关类别 ]:
[参考文献]
[1]. An J, et al. Efficacy and Safety of the Anti-PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study. Clin Cancer Res. 2022 Dec 1;28(23):5098-5106.
[2]. Lu S, et al. 143P Efficacy and safety of the anti-PD-L1 monoclonal antibody Socazolimab in combination with carboplatin and etoposide for extensive-stage small cell lung cancer: Results from the phase Ib clinical trial[J]. Annals of Oncology, 2022, 33: S99.
[3]. Li Y, et al. 1207P Neoadjuvant PD-L1 inhibitor (socazolimab) plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, double-blind phase II study[J]. Annals of Oncology, 2022, 33: S1101.
[4]. Duan R, et al. Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma[J]. 2022.
[5]. Zhou Y, et al. First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti-PD-L1 Antibody ZKAB001. Clin Cancer Res. 2023 Feb 16;29(4):764-774.
索卡佐利单抗物理化学性质
推荐生产厂家/供应商：
【索卡佐利单抗】化源网提供索卡佐利单抗CAS号2305043-30-3，索卡佐利单抗MSDS及其说明、性质、英文名、生产厂家、作用/用途、分子量、密度、沸点、熔点、结构式等。CAS号查询索卡佐利单抗上化源网，专业又轻松。>>电脑版：索卡佐利单抗
标题：索卡佐利单抗_用途_结构式_性质_索卡佐利单抗CAS号【2305043-30-3】_化源网 地址：https://www.chemsrc.com/amp/cas/2305043-30-3_1732780.html